Anzeige
Mehr »
Login
Mittwoch, 22.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Mit dieser Aktie könntest Du von der Cannabis-Legalisierungswelle profitieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2N951 | ISIN: SE0010133785 | Ticker-Symbol: AC6
Frankfurt
22.05.24
09:17 Uhr
0,150 Euro
0,000
0,00 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ALZECURE PHARMA AB Chart 1 Jahr
5-Tage-Chart
ALZECURE PHARMA AB 5-Tage-Chart

Aktuelle News zur ALZECURE PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
15.05.AlzeCure Pharma: Eli Lilly's and AstraZeneca's Former Head of Research Dr. Jan Lundberg Elected as a New Board Member342STOCKHOLM, SWEDEN / ACCESSWIRE / May 15, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB, a pharmaceutical company that develops candidate drugs for CNS diseases, focusing on Alzheimer's...
► Artikel lesen
14.05.Communiqué from the Annual General Meeting of AlzeCure Pharma on 14 May 2024336STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) Today, 14 May 2024, the annual general meeting was held in AlzeCure Pharma AB (publ) (the "Company"). Below is a...
► Artikel lesen
13.05.AlzeCure Pharma: AlzeCure Reports Anti-Inflammatory Effects with NeuroRestore ACD856 with Relevance to Alzheimer's Leading to New Patent Application170STOCKHOLM, SWEDEN / ACCESSWIRE / May 13, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting...
► Artikel lesen
30.04.Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares of AlzeCure Pharma AB220With effect from May 02, 2024, the subscription rights in AlzeCure Pharma AB will be traded on First North Growth Market. Trading will continue up until and including May 14, 2024. Instrument: Subscription...
► Artikel lesen
25.04.AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - March 2024464STOCKHOLM, SWEDEN / ACCESSWIRE / April 25, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January - March...
► Artikel lesen
25.04.XFRA CAPITAL ADJUSTMENT INFORMATION - 25.04.2024187Das Instrument AB2 NL0011540547 ABN AMRO BANK DR/EO1 EQUITY wird cum Kapitalmassnahme gehandelt am 25.04.2024 und ex Kapitalmassnahme am 26.04.2024 The instrument AB2 NL0011540547 ABN AMRO BANK DR/EO1...
► Artikel lesen
10.04.AlzeCure Pharma: Eli Lilly's and AstraZeneca's Former Head of Research Dr. Jan Lundberg Invests in AlzeCure and is Proposed for Election to its Board2.288STOCKHOLM, SWEDEN / ACCESSWIRE / April 10, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB ("AlzeCure" or "the Company"), a pharmaceutical company that develops candidate drugs for CNS...
► Artikel lesen
04.04.AlzeCure Pharma Publishes its Annual Report for 2023197STOCKHOLM, SE / ACCESSWIRE / April 4, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule...
► Artikel lesen
03.04.AlzeCure Pharma: AlzeCure Presents New Data Regarding the TrkA-NAM Pain Project at IASP 2024221STOCKHOLM, SWEDEN / ACCESSWIRE / April 3, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for CNS diseases...
► Artikel lesen
14.03.AlzeCure Pharma: AlzeCure to Partake in Redeye Theme: Alzheimer on March 21250STOCKHOLM, SWEDEN / ACCESSWIRE / March 14, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops small molecule drug candidates...
► Artikel lesen
07.03.AlzeCure Pharma: AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at Leading Alzheimer's Conference543STOCKHOLM, SWEDEN / ACCESSWIRE / March 7, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops small molecule drug candidates...
► Artikel lesen
05.03.AlzeCure Pharma: AlzeCure Publishes Clinical Results Supporting Continued Development of NeuroRestore ACD856 Against Alzheimer's401STOCKHOLM, SWEDEN / ACCESSWIRE / March 5, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops small molecule drug candidates...
► Artikel lesen
29.02.AlzeCure Pharma: AlzeCure's Alzheimer's Project NeuroRestore ACD856 is Granted an Additional Patent314STOCKHOLM, SWEDEN / ACCESSWIRE / February 29, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for CNS...
► Artikel lesen
27.02.AlzeCure Pharma: AlzeCure Publishes its Year-end Report for January - December 2023312STOCKHOLM, SWEDEN / ACCESSWIRE / February 27, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its Year-end report for the period January -...
► Artikel lesen
12.02.AlzeCure Pharma Broadcasts Live Expert Event on Alzheimer's Around Highly Current Gamma-Secretase Modulators260STOCKHOLM, SE / ACCESSWIRE / February 12, 2024 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for CNS diseases...
► Artikel lesen
06.02.AlzeCure Pharma: AlzeCure Gets Late Breaking Abstract of New Preclinical Data with ACD856 Accepted at AD/PD 2024 Conference901STOCKHOLM, SWEDEN / ACCESSWIRE / February 6, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for CNS diseases...
► Artikel lesen
31.01.AlzeCure Pharma: AlzeCure CEO Martin Jönsson to Present at the International Investor Conference BioCapitalEurope543STOCKHOLM, SWEDEN / ACCESSWIRE / January 31, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for CNS diseases...
► Artikel lesen
29.01.AlzeCure Selects Promising Drug Candidate ACD1372
29.01.AlzeCure Pharma: AlzeCure Selects Drug Candidate and Enters Next Phase of Development with TrkA-NAM ACD137 against Severe Pain347STOCKHOLM, SWEDEN / ACCESSWIRE / January 29, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR, a pharmaceutical company that develops a broad portfolio of small...
► Artikel lesen
17.01.The Government Draws Attention to Swedish Alzheimer's Research and Together with the Swedish Alzheimer's Foundation Visit AlzeCure Pharma403STOCKHOLM, SWEDEN / ACCESSWIRE / January 17, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for CNS diseases...
► Artikel lesen
Seite:  Weiter >>
41 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1